{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:53:41Z","timestamp":1791824021508,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T00:00:00Z","timestamp":1550188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003921","name":"Australian Government Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Disease","doi-asserted-by":"publisher","award":["HHSN272201400006C"],"award-info":[{"award-number":["HHSN272201400006C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"Department of Health and Human Services, USA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.antiviral.2019.02.007","type":"journal-article","created":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T11:24:41Z","timestamp":1550057081000},"page":"91-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012\u20132018"],"prefix":"10.1016","volume":"164","author":[{"given":"Paulina","family":"Koszalka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Tilmanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merryn","family":"Roe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3293-6279","authenticated-orcid":false,"given":"Dhanasekaran","family":"Vijaykrishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aeron C.","family":"Hurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"45","key":"10.1016\/j.antiviral.2019.02.007_bib1","doi-asserted-by":"crossref","first-page":"6324","DOI":"10.1016\/j.vaccine.2009.03.029","article-title":"MDCK cells that express proteases TMPRSS2 and HAT provide a cell system to propagate influenza viruses in the absence of trypsin and to study cleavage of HA and its inhibition","volume":"27","author":"B\u00f6ttcher","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2019.02.007_bib2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ejps.2017.10.027","article-title":"Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system","volume":"111","author":"de Mello","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.antiviral.2019.02.007_bib3","doi-asserted-by":"crossref","first-page":"e0119115","DOI":"10.1371\/journal.pone.0119115","article-title":"Adamantane-resistant influenza a viruses in the world (1902\u20132013): frequency and distribution of M2 gene mutations","volume":"10","author":"Dong","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.antiviral.2019.02.007_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jcv.2007.10.019","article-title":"Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors","volume":"41","author":"Escuret","year":"2008","journal-title":"J. Clin. Virol."},{"issue":"7","key":"10.1016\/j.antiviral.2019.02.007_bib5","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1093\/jac\/dkv065","article-title":"Influenza viruses with B\/Yamagata-and B\/Victoria-like neuraminidases are differentially affected by mutations that alter antiviral susceptibility","volume":"70","author":"Farrukee","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"10.1016\/j.antiviral.2019.02.007_bib6","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2019.24.3.1800666","article-title":"Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016\/17 and 2017\/18 seasons","volume":"24","author":"Gubareva","year":"2019","journal-title":"Euro Surveill."},{"issue":"2","key":"10.1016\/j.antiviral.2019.02.007_bib7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3201\/eid1502.081031","article-title":"Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007\u201308","volume":"15","author":"Hauge","year":"2009","journal-title":"Emerg. Infect. Dis."},{"issue":"10","key":"10.1016\/j.antiviral.2019.02.007_bib8","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.antiviral.2019.02.007_bib9","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1086\/656408","article-title":"Early oseltamivir treatment of influenza in children 1\u20133 years of age: a randomized controlled trial","volume":"51","author":"Heinonen","year":"2010","journal-title":"Clin. Infect. Dis."},{"issue":"18","key":"10.1016\/j.antiviral.2019.02.007_bib10","doi-asserted-by":"crossref","first-page":"9427","DOI":"10.1128\/JVI.00373-10","article-title":"Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model","volume":"84","author":"Hurt","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.02.007_bib11","series-title":"IDweek 2018","article-title":"Phase 3 trial of baloxavir marboxil in high risk influenza patients (CAPSTONE-2 study)","author":"Ison","year":"2018"},{"issue":"11","key":"10.1016\/j.antiviral.2019.02.007_bib12","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40261-018-0697-2","article-title":"Evaluation of drug\u2013drug interaction potential between baloxavir marboxil and oseltamivir in healthy subjects","volume":"38","author":"Kawaguchi","year":"2018","journal-title":"Clin. Drug Investig."},{"issue":"4","key":"10.1016\/j.antiviral.2019.02.007_bib13","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1086\/505868","article-title":"A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003\u20132004 and 2004\u20132005 influenza seasons","volume":"43","author":"Kawai","year":"2006","journal-title":"Clin. Infect. Dis."},{"issue":"12","key":"10.1016\/j.antiviral.2019.02.007_bib14","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s40261-018-0710-9","article-title":"Safety, tolerability, and pharmacokinetics of the novel anti-influenza agent baloxavir marboxil in healthy adults: phase I study findings","volume":"38","author":"Koshimichi","year":"2018","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.antiviral.2019.02.007_bib15","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.antiviral.2018.07.001","article-title":"Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016\u20132017","volume":"157","author":"Lackenby","year":"2018","journal-title":"Antivir. Res."},{"issue":"15","key":"10.1016\/j.antiviral.2019.02.007_bib16","doi-asserted-by":"crossref","first-page":"8418","DOI":"10.1128\/JVI.77.15.8418-8425.2003","article-title":"Overexpression of the \u03b1-2, 6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors","volume":"77","author":"Matrosovich","year":"2003","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.antiviral.2019.02.007_bib17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1743-422X-7-53","article-title":"A two-year survey of the oseltamivir-resistant influenza A (H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir","volume":"7","author":"Matsuzaki","year":"2010","journal-title":"Virol. J."},{"key":"10.1016\/j.antiviral.2019.02.007_bib18","series-title":"Open Forum Infectious Diseases","article-title":"S-033447\/S-033188, a novel small molecule inhibitor of cap-dependent endonuclease of influenza A and B virus: in vitro antiviral activity against clinical strains","author":"Noshi","year":"2016"},{"key":"10.1016\/j.antiviral.2019.02.007_bib19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.antiviral.2018.10.008","article-title":"In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit","volume":"160","author":"Noshi","year":"2018","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.antiviral.2019.02.007_bib20","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.1038\/s41598-018-27890-4","article-title":"Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil","volume":"8","author":"Omoto","year":"2018","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.antiviral.2019.02.007_bib21","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2165\/00044011-200323090-00002","article-title":"Clinical benefits with oseltamivir in treating influenza in adult populations","volume":"23","author":"Singh","year":"2003","journal-title":"Clin. Drug Investig."},{"issue":"2","key":"10.1016\/j.antiviral.2019.02.007_bib22","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1086\/509925","article-title":"Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children","volume":"44","author":"Sugaya","year":"2007","journal-title":"Clin. Infect. Dis."},{"issue":"43","key":"10.1016\/j.antiviral.2019.02.007_bib23","article-title":"Low interim influenza vaccine effectiveness, Australia","volume":"22","author":"Sullivan","year":"2017","journal-title":"Euro Surveill."},{"key":"10.1016\/j.antiviral.2019.02.007_bib24","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.3389\/fmicb.2018.03026","article-title":"Susceptibility of influenza viruses to the novel cap-dependent endonuclease inhibitor baloxavir marboxil","volume":"9","author":"Takashita","year":"2018","journal-title":"Front. Microbiol."},{"issue":"1","key":"10.1016\/j.antiviral.2019.02.007_bib25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1750-2659.2009.00073.x","article-title":"Estimates of US influenza\u2010associated deaths made using four different methods","volume":"3","author":"Thompson","year":"2009","journal-title":"Influenza Other Respir. Viruses"},{"key":"10.1016\/j.antiviral.2019.02.007_bib26","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.antiviral.2017.10.002","article-title":"The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide","volume":"147","author":"Tilmanis","year":"2017","journal-title":"Antivir. Res."},{"issue":"2","key":"10.1016\/j.antiviral.2019.02.007_bib27","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A simple statistical parameter for use in evaluation and validation of high throughput screening assays","volume":"4","author":"Zhang","year":"1999","journal-title":"J. Biomol. Screen"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218306983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218306983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T16:51:34Z","timestamp":1662915094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218306983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":27,"alternative-id":["S0166354218306983"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.02.007","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/498766","asserted-by":"object"}]},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012\u20132018","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}